Stock Details
NVO is Novo Nordisk A/S's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 106.20$. Average daily volumn in 3 months 1.69M. Market cap 225.62B



Stock symbol : NVO. Exchange : NYSE. Currency : USD
Lastest price : 99.63$. Total volume : 1.09M. Market state POSTPOST
Click reload if you want to check the lastest price on market!!!

Novo Nordisk A/S (NVO)
Last Price
99.63$
Change
-0.76
Volume
1.09M

Previous Close100.39
Open100.20
Day Range99.57-100.72
Bid99.99 x 900
Ask101.79 x 1k
Volume1.09M
Average Volume1.69M
Market Cap225.62B
BetaN/A
52 Week Range91.51-122.16
Trailing P/E34.12
Foward P/E26.78
Dividend (Yield %)N/A
Ex-Dividend DateN/A



Financial Details


According to Novo Nordisk A/S's financial reports the company's revenue in 2021 were 140.8B an increase( +11.11%) over the years 2020 revenue that were of 126.95B. In 2021 the company's total earnings were 47.76B while total earnings in 2020 were 42.14B( +11.9%).


Loading ...



Organization

Market Cap:
225.62B
Revenue:
140.8B
Total Assets:
194.51B
Total Cash:
10.72B


News about "Novo Nordisk A/S"

novo-nordisk-as-nysenvo-upgraded-by-oddo-bhf-to-outperform-image

Novo Nordisk A/S (NYSE:NVO) Upgraded by Oddo Bhf to “Outperform”

Source from : Defense World - 1 days ago

Oddo Bhf upgraded shares of Novo Nordisk A/S (NYSE:NVO – Get Rating) from a neutral rating to an outperform rating in a research report released on Thursday, The Fly reports. A number of other ...See details»


novo-nordisk-as-share-repurchase-programme-image

Novo Nordisk A/S – Share repurchase programme

Source from : Yahoo - 4 days ago

On 3 August 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the ...See details»


allworth-financial-lp-acquires-138-shares-of-novo-nordisk-as-nysenvo-image

Allworth Financial LP Acquires 138 Shares of Novo Nordisk A/S (NYSE:NVO)

Source from : Defense World - 3 days ago

Allworth Financial LP grew its stake in shares of Novo Nordisk A/S (NYSE:NVO – Get Rating) by 34.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange ...See details»


top-analyst-reports-for-novo-nordisk-suncor-energy-nasdaq-image

Top Analyst Reports for Novo Nordisk, Suncor Energy, & Nasdaq

Source from : YAHOO!Finance - 17 hours ago

Today's Research Daily features new research reports on 12 major stocks, including Novo Nordisk A/S (NVO), Suncor Energy Inc. (SU) and Nasdaq, Inc. (NDAQ).See details»


ventus-and-novo-nordisk-enter-nlrp3-inhibitor-development-deal-image

Ventus and Novo Nordisk enter NLRP3 inhibitor development deal

Source from : Pharmaceutical Technology - 23 hours ago

Ventus Therapeutics and Novo Nordisk have signed a licence agreement for developing peripherally-restricted NLRP3 inhibitor candidates.See details»


montreals-ventus-therapeutics-strikes-us700-million-plus-deal-with-pharma-giant-novo-nordisk-image

Montreal’s Ventus Therapeutics strikes US$700-million-plus deal with pharma giant Novo Nordisk

Source from : The Globe and Mail - 2 days ago

Montreal biotechnology company Ventus Therapeutics Inc. has struck a development and licensing deal with pharma giant Novo Nordisk A/S NVO-N that could be worth more than US$700-million ($960-million) ...See details»


novo-nordisk-grabs-nash-drug-from-ventus-in-703m-deal-image

Novo Nordisk grabs NASH drug from Ventus in $703m deal

Source from : pharmaphorum - 1 days ago

Denmark’s Novo Nordisk has agreed to pay $70 million to license rights to a drug developed by Ventus Therapeutics with potential in non-alcoholic steatohepatitis (NASH) and several other diseases ...See details»


novo-nordisk-pays-70m-for-a-phase-1-ready-cardiometabolic-disorder-drug-image

Novo Nordisk pays $70M for a Phase 1-ready cardiometabolic disorder drug

Source from : MedCity News - 1 days ago

Novo Nordisk is acquiring global rights to a Ventus Therapeutics drug candidate with potential applications in cardiometabolic disorders such as NASH and chronic kidney disease. The small molecule ...See details»


ventus-sells-its-lead-drug-candidate-to-novo-nordisk-image

Ventus sells its lead drug candidate to Novo Nordisk

Source from : BioPharma Dive - 1 days ago

The biotechnology startup will part with its lead drug candidate, an anti-inflammatory small molecule, in Novo Nordisk’s bet on inflammasome treatments.See details»


Ventus Therapeutics Enters Exclusive Development and License Agreement with Novo Nordisk for NLRP3 Inhibitor Program

Source from : Daily Herald - 2 days ago

Collaboration combines Ventus’ lead NLRP3 inhibitor program with Novo Nordisk’s deep expertise across cardiometabolic diseases Ventus Therapeutics, Inc., a biopharmaceutical company utilizing ...See details»


foundation-behind-novo-nordisk-to-invest-200m-in-building-quantum-research-powerhouse-image

Foundation behind Novo Nordisk to invest $200M in building quantum research ‘powerhouse’

Source from : BioPharma Dive - 9 days ago

The grant is one of the Novo Nordisk Foundation’s largest and will fund a 12-year research collaboration to construct a quantum computer dedicated to the life sciences.See details»


ventus-therapeutics-cuts-70m-deal-with-danish-drug-giant-novo-nordisk-image

Ventus Therapeutics cuts $70m deal with Danish drug giant Novo Nordisk

Source from : The Boston Globe on MSN - 2 days ago

The local company is working on drugs to treat conditions such as nonalcoholic fatty liver disease and chronic kidney disease.See details»


novo-nordisk-foundation-investing-200m-for-first-quantum-computer-for-life-sciences-research-image

Novo Nordisk Foundation investing $200M for first quantum computer for life sciences research

Source from : labiotech - 9 days ago

The Novo Nordisk Foundation has awarded a $200M grant for the first full-scale quantum computer to develop new medicines.See details»


Q&A: Novo Nordisk’s Keith Middleton on its latest DE&I efforts

Source from : MM&M - 8 days ago

How is Novo Nordisk differentiating what it’s doing compared to other players in the space? Middleton: The fact that we work in the therapeutic areas of the diseases that we do, it highlights a huge ...See details»